[ad_1] Results from Novo Nordisk, presented at ObesityWeek®, showed treatment with semaglutide injection 2.4 mg resulted in significant reductions in hospital admissions as well as overall time spent in the hospital1 Cardiovascular disease represents the […]
[ad_1] Data unveils new insights into treatment for type 2 diabetes, obesity, cardiovascular, kidney and liver diseases Cardiometabolic diseases, including cardiovascular disease, obesity, type 2 diabetes, and MASH, are increasing in prevalence in the U.S. […]
